Screener
Enliven Therapeutics ELVN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $1,640 | $2,159 |
| Accrued expenses and other current liabilities | 9,847 | 14,409 |
| Total current liabilities | 11,487 | 16,568 |
| Total liabilities | 11,487 | 16,568 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none | — | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total current liabilities?
- Enliven Therapeutics (ELVN) reported total current liabilities of $11.49M in Q1 2026.
- How has Enliven Therapeutics's total current liabilities changed year-over-year?
- Enliven Therapeutics's total current liabilities decreased by 17.8% year-over-year, from $13.97M to $11.49M.
- What is the long-term trend for Enliven Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total current liabilities has grown at a 21.5% compound annual growth rate (CAGR), from $6.25M to $16.57M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Enliven Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude